# US 2012/0252883 A1 · Method and Composition to Increase Radiation-Induced Tumor Therapeutic Effects

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252883 A1
- Document ID: US20120252883A1
- Status: Published application
- Kind: A1
- Application number: 13/513,890
- Filed: 2010-12-07
- Published: 2012-10-04
- Earliest claimed: 2009-12-08
- Assignees: Vascular Biogenics, Ltd.; Memorial Sloan-Kettering Cancer Center ("Mskcc")
- Inventors: Richard N. Kolesnick; Branka Stancevic; Michel Sadelain; Zvi Fuks; Nira Varda-Bloom; Dror Harats
- Web page: https://patentgrep.com/patent/US20120252883A1

## CPC

- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 35/761: Adenovirus
- A61K 41/0038: {Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy (radiotherapy per se A61N5/10)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61N 5/10: X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy (A61N5/01 takes precedence)
- A61P 35/00: Antineoplastic agents
- C12N 9/16: acting on ester bonds (3.1)
- C12N 15/86: Viral vectors
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61N 2005/1098: {Enhancing the effect of the particle by an injected agent or implanted device}
- C12N 2710/10332: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2710/10343: viral genome or elements thereof as genetic vector
- C12N 2830/002: inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
- C12N 2830/008: cell type or tissue specific enhancer/promoter combination
- C12N 2830/15: chimeric enhancer/promoter combination
- C12N 2830/85: mammalian
- C12Y 301/04012: Sphingomyelin phosphodiesterase (3.1.4.12)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

Disclosed herein are methods and compositions for treating cancer by increasing radiation-induced damage to cancer without increasing radiation-induced side effects by increasing secretory ASMase levels specifically in tumor endothelium, and inducing apoptosis of tumor endothelial cells by treating the tumor with radiation. ASMase levels are increased in tumor endothelium by administration of a recombinant DNA construct comprising a region coding for a functional ASMase linked to particular transcriptional regulatory sequences that confer tissue-specific expression of ASMase.

## Claims

### Claim 1

A recombinant DNA construct comprising a region coding for a functional secretory ASMase linked to transcriptional regulatory sequences that confer tissue-specific expression of said secretory ASMase.

### Claim 2 (depends on 1)

The recombinant DNA construct of claim 1, where the transcriptional regulatory sequences are specific for tumor endothelium

### Claim 3 (depends on 1)

The recombinant DNA construct of claim 1, where the transcriptional regulatory sequences are specific for the angiogenic endothelium of tumors.

### Claim 4 (depends on 3)

The recombinant DNA construct of claim 3, wherein said angiogenic endothelium-specific transcriptional regulatory sequences are selected from the group consisting of promoters and enhancers.

### Claim 5 (depends on 4)

The recombinant DNA construct of claim 4, wherein said promoter is pre-proendothelin-1 promoter or modifications thereof.

### Claim 6 (depends on 5)

The recombinant DNA construct of claim 5, wherein said promoter is PPE-1(×3).

### Claim 7 (depends on 4)

The recombinant DNA construct of claim 4, wherein said enhancer is HIF2α-Ets-1 enhancer.

### Claim 8 (depends on 1)

An expression vector comprising the recombinant DNA construct of claim 1.

### Claim 9 (depends on 8)

The expression vector of claim 8, wherein the expression vector is a viral expression vector.

### Claim 10 (depends on 9)

The expression vector of claim 9, wherein the viral expression vector is replication defective.

### Claim 11 (depends on 9)

The expression vector of claim 9, wherein the viral expression vector is an adenovirus vector.

### Claim 12

A method to treat cancer by increasing radiation-induced damage to a tumor without increasing radiation-induced side effects comprising:
(1) increasing secretory ASMase levels specifically in tumor endothelium, and
(2) inducing apoptosis of tumor endothelial cells by treating the tumor with radiation.

### Claim 13 (depends on 12)

The method of claim 12, where said cancer is a solid tumor.

### Claim 14 (depends on 12)

The method of claim 12, where the increase in radiation-induced damage to the tumor without an increase in radiation-induced side effects is achieved by sensitizing the tumor to radiation.

### Claim 15 (depends on 14)

The method of claim 14, where the increase in radiation-induced damage to the tumor without an increase in radiation-induced side effects is achieved by sensitizing the angiogenic epithelium of the tumor to radiation.

### Claim 16 (depends on 12)

The method of claim 12, wherein secretory ASMase levels are increased specifically in tumor endothelium through the administration of a gene therapy construct.

### Claim 17 (depends on 1, 12)

The method of claim 12, wherein the gene therapy construct is the construct of claim 1.

### Claim 18 (depends on 16)

The method of claim 16, wherein ceramide levels are increased specifically in tumor endothelium through the administration of said gene therapy construct.

### Claim 19 (depends on 1)

Use of the construct of claim 1 in the manufacture of a medicament for treating cancer wherein said construct increased ASMase levels in tumor endothelium and thereby increases radiation-induced damage to a tumor without increasing radiation-induced side effects.

### Claim 20 (depends on 18)

The use of claim 18, where said cancer is a solid tumor.

### Claim 21 (depends on 18)

The use of claim 18, where the increase in radiation-induced damage to the tumor without an increase in radiation-induced side effects is achieved by sensitizing the tumor to radiation.

### Claim 22 (depends on 21)

The use of claim 21, where the increase in radiation-induced damage to the tumor without an increase in radiation-induced side effects is achieved by sensitizing the angiogenic epithelium of the tumor to radiation.

### Claim 23 (depends on 12)

The use of claim 12, wherein secretory ASMase levels are increased specifically in tumor endothelium through the administration of said construct.
